The Pediatric Diffuse Intrinsic Pontine Glioma drugs in development market research report provides comprehensive information on the therapeutics under development for Pediatric Diffuse Intrinsic Pontine Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pediatric Diffuse Intrinsic Pontine Glioma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pediatric Diffuse Intrinsic Pontine Glioma and features dormant and discontinued products.
GlobalData tracks 62 drugs in development for Pediatric Diffuse Intrinsic Pontine Glioma by 58 companies/universities/institutes. The top development phase for Pediatric Diffuse Intrinsic Pontine Glioma is phase i with 23 drugs in that stage. The Pediatric Diffuse Intrinsic Pontine Glioma pipeline has 50 drugs in development by companies and 12 by universities/ institutes. Some of the companies in the Pediatric Diffuse Intrinsic Pontine Glioma pipeline products market are: Bristol-Myers Squibb, Pfizer and Novartis.
The key targets in the Pediatric Diffuse Intrinsic Pontine Glioma pipeline products market include Cyclin Dependent Kinase 6, Cyclin Dependent Kinase 4, and CD276 Antigen.
The key mechanisms of action in the Pediatric Diffuse Intrinsic Pontine Glioma pipeline product include Cyclin Dependent Kinase 4 Inhibitor with three drugs in Phase II. The Pediatric Diffuse Intrinsic Pontine Glioma pipeline products include 13 routes of administration with the top ROA being Oral and 11 key molecule types in the Pediatric Diffuse Intrinsic Pontine Glioma pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Pediatric Diffuse Intrinsic Pontine Glioma overview
Pediatric diffuse intrinsic pontine glioma (DIPG) is a rare and aggressive type of brain tumor that primarily affects children, usually between the ages of five and 10 years. This tumor arises in the brainstem, specifically in the region known as the pons, which controls essential bodily functions such as breathing, heart rate, and muscle control. DIPG tumor location in the brainstem makes surgical removal challenging due to their diffuse and infiltrative nature. These tumors typically grow rapidly and infiltrate surrounding brain tissue, causing compression and disruption of crucial neurological functions. Symptoms of DIPG often arise from the tumor’s location and include difficulty walking, problems with coordination, weakness in the arms or legs, double vision, difficulty swallowing, facial weakness, and changes in mood or behavior. Symptoms can progress rapidly, leading to severe neurological deficits.
For a complete picture of Pediatric Diffuse Intrinsic Pontine Glioma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
